Abstract
Biological treatment with inhibitors of the pro-inflammatory cytokine TNF-alpha has dramatically improved the disease course of several chronic rheumatologic conditions. Adverse events (AEs) are primarily infections and hypersensitivity reactions. Demyelinizing neurological symptoms resembling multiple sclerosis (MS) have been described as a rare AE. During about 10-year use of anti TNF-alpha, the Danish Medicines Agency has recorded eight cases of MS like AEs. The objective of this study was to estimate the incidence of demyelinizing AEs both in the central and peripheral nervous system after treatment with anti TNF-alpha in a cohort of patients from a large rheumatologic outpatient clinic in Copenhagen. In a 4-year period from January 2008 to December 2011, approximately 550 patients annually were undergoing treatment with anti TNF-alpha inhibitors in our department. We collected data on all patients who developed neurological symptoms during this time period. We found six patients with signs of demyelinizing neurological disorders: four resembling MS, one MS-like condition, and one multifocal motor neuropathy. During a relatively short time period, we found a remarkably high number of neurological demyelinizing AEs probably linked to anti TNF-alpha treatment. The AEs were not associated with a single anti TNF-alpha agent and were thus presumably a class effect. The data presented suggest that neurological AEs may be underreported. We advocate that physicians handling patients during treatment with TNF inhibitors are aware of this potentially serious AE and report these events to the proper medical authorities.
Similar content being viewed by others
References
Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465
Liu J, Marino MW, Wong G et al (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78–83
Tanno M, Nakamura I, Kobayshi S et al (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25(6):929–933
Lozeron P, Denier C et al (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490–497
Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475–481
Ascherio A, Munger K (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28:17–28
Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol 257:1421–1431
Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40:330–337
Winthrop KL, Chen L, Fraunfelder FW et al (2013) Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biological thERapy (SABER) study. Am J Ophthalmol 155:183–189
Gregory AP, Dendrou CA, Attfield KE et al (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488(7412):508–511. doi:10.1038/nature11307
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Theibich, A., Dreyer, L., Magyari, M. et al. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol 33, 719–723 (2014). https://doi.org/10.1007/s10067-013-2419-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2419-8